Physician profile
Mona S Ismail
NPI 1053355834
$2,228.17
in general payments reported to CMS, 2019-2025
20 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $349 · 2023: $1,190 · 2024: $583 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.80 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $305.54 | 2022-2024 | Spravato, Invega Sustenna |
| Abbvie INC. | $284.02 | 2022-2024 | |
| Corium, LLC | $260.71 | 2022-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.67 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $192.97 | 2022-2023 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $164.93 | 2022-2023 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $159.40 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $86.46 | 2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $83.13 | 2022-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $65.20 | 2023-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $57.78 | 2023-2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $57.59 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $55.01 | 2023 | Austedo, Austedo Xr |
| Almatica Pharma LLC | $50.30 | 2023 | Sertraline Hcl, Loreev Xr |
| Merck Sharp & Dohme LLC | $47.27 | 2022-2023 | Belsomra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $36.32 | 2022-2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $33.64 | 2023 | Quviviq |
| Alkermes, INC. | $28.30 | 2023-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $16.39 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.